Global Active Pharmaceutical Ingredients (API) Market Report by Drug Type (Innovative, Generic), Synthesis (Synthetic, Biotech), Type of Manufacturer (Captive, Merchant), Application (Cardiovascular Diseases, Oncology, Central Nervous System and Neurology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, Other Applications), Regions and Company Analysis 2024-2032

Global Active Pharmaceutical Ingredients (API) Market Analysis

Global Active Pharmaceutical Ingredients (API) Market share was worth US$ 212.12 Billion in 2023. It is anticipated to grow at a CAGR of 6.60% from 2024 to 2032 and will be valued at US$ 377.05 Billion by 2032.

The part of a prescription or over-the-counter drug that has the desired effect on health is called an active pharmaceutical ingredient (API). A prescription drug's generic name is the same as its active pharmaceutical ingredient (API). Combination treatments contain several active substances, each of which may have a unique effect or address distinct symptoms. Two main categories can be used to classify APIs: synthetic and natural. Based on the type of synthesis utilized, synthetic APIs are further divided into generic and novel categories. Pharmaceutical goods' therapeutic qualities and clinical results are determined by their active pharmaceutical components, which form their base. A key element in guaranteeing the efficacy and safety of pharmaceuticals is the exact dosing and thoughtful selection of APIs.

Global Active Pharmaceutical Ingredients (API) Market Growth Trends

• The global active pharmaceutical ingredients (APIs) market is driven by the prevalence of chronic diseases such as diabetes, heart disease, stroke, and cancer, which are important sources of morbidity and mortality.
• 10.5% of adults (20–79 years old) have diabetes, according to the IDF Diabetes Atlas (2021), and nearly half of them are unaware that they have the disease. According to IDF forecasts, 783 million adults, or 1 in 8 of the population, will have diabetes by 2045—a 46% rise.
• According to the World Health Organization (WHO), there will likely be 9.7 million fatalities and 20 million new cancer cases in 2022. 53.5 million people were predicted to still be alive five years after receiving a cancer diagnosis. One in five humans will be infected by cancer at some point in their lives (one in nine men and one in twelve women will pass away from the illness).
• In January 2023 - In India, BDR Pharmaceutical has introduced a generic version of Apalutamide, a medication used to treat prostate cancer. In India, the medication was introduced under the trade name APATIDE to treat prostate cancer that is resistant to non-metastatic castration as well as metastatic castration-sensitive prostate cancer.
• In November 2023 - Zepbound, a medication for treating obesity, was approved by the US Food and Drug Administration on Wednesday. The medication's active component is known as tirzepatide. It is marketed as a diabetic medication and is produced by the pharmaceutical company Eli Lilly and Co. under the brand name Mounjaro.
• The global active pharmaceutical ingredients (APIs) industry is driven by the growing number of elderly people who need medication. People usually need more medication as they get older to treat chronic illnesses including dementia, arthritis, and hypertension.
• The WHO estimates that about 55 million individuals worldwide suffer from dementia at this time. Currently ranking as the seventh most common cause of death worldwide, dementia is also a major contributor to impairment and dependency in the elderly population. As the most prevalent type of dementia, Alzheimer's disease may be a factor in 60–70% of cases.
• Despite reservations regarding Leqembi's accessibility, cost, and safety, the Food and Drug Administration completely approved the medication for Alzheimer's. Leqembi is a medication that is part of the amyloid beta-directed antibodies medicine class and contains the active ingredient lecanemab-irmb. Adults with mild cognitive impairment or mild dementia due to Alzheimer's disease may begin Leqembi therapy.
• The pharmaceutical sector is driven by efficiency, quality, and innovation due to technological breakthroughs in the production of active pharmaceutical ingredients, or APIs. API yield and purity are increased while costs and environmental impact are decreased by improved manufacturing techniques including biocatalysis and continuous manufacturing. Production workflows are optimized by automation and data analytics, which speeds up the development and expansion of API manufacturing. Pharmaceutical businesses can now design complicated APIs, fulfill rising demand, and stay competitive in the worldwide API market thanks to these innovations.

United States Active Pharmaceutical Ingredients (API) Market

• The US active pharmaceutical ingredients market is being driven by rising rates of infectious diseases, genetic disorders, and chronic illnesses.
• The CDC reports that the incidence of infectious disorders such as Lyme disease was 34,945, salmonella was 58,371, and tuberculosis was 8,916, among others.
• Physicians and patients are anticipated to use APIs more frequently as a result of the growing development and clinical trial activity for biologics and biosimilar medications, as well as the growing number of new therapeutic class approvals. This is expected to fuel the expansion for the United States active pharmaceutical ingredients market.
• In comparison to 2022, the U.S. Food and Drug Administration approved almost 50% more new medications in 2023. FDA nods for novel treatments with an active component or molecule that has not been approved before increased to 55 in 2023 from 37 in 2022 and 51 in 2021. Along with the 55 novel medications, it also authorized five gene therapies. These included a treatment for sickle cell disease from Vertex Pharmaceuticals (VRTX.O) and a gene editing technique from CRISPR Therapeutics (CRSP.BN).

Global Active Pharmaceutical Ingredients (API) Industry News

Pfizer, Inc., Novartis International AG, Sanofi, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., ELI Lilly and Company, GlaxoSmithKline, Merck & Co., Inc., Abbvie Inc. are the leading companies of the global active pharmaceutical ingredients (API) industry.

• In December 2023 - Novo Nordisk declared that it would construct a new facility for active pharmaceutical ingredients (API) in Kalundborg, Denmark, in order to increase its current manufacturing capacity.
• In October 2023 - A binding contract has been signed by IQuest Enterprises to purchase Viatris's Indian active pharmaceutical ingredients (API) business.
• In October 2023 - The portfolio of high-performing pharmaceutical ingredient solutions from Clariant has been expanded to include new products that will aid in the development of safe and efficient medications. In order to position itself as the industry's one-stop shop for solutions, Clariant will introduce three new VitiPure® excipients at CPHI Barcelona. These excipients enable a wide range of Active Pharmaceutical Ingredient (API) formulations and administration routes, even for sensitive ones like mRNA vaccines and biologic medications.
• In September 2023 - In order to sell its 75% ownership in Glenmark Lifesciences, Glenmark Pharmaceuticals and Nirma Limited have entered into a share purchase agreement. 
• In July 2023 - Teva evaluates the sale of a $2 billion unit of active ingredients.

Drug Type – Market is broken up into 2 viewpoints:

1.    Innovative
2.    Generic

Synthesis – Market is broken up into 2 viewpoints:

1.    Synthetic
2.    Biotech

Type of Manufacturer – Market is broken up into 2 viewpoints:

1.    Captive
2.    Merchant

Application – Market is broken up into 11 viewpoints:

1.    Cardiovascular Diseases
2.    Oncology
3.    Central Nervous System and Neurology
4.    Orthopedic
5.    Endocrinology
6.    Pulmonology
7.    Gastroenterology
8.    Nephrology
9.    Ophthalmology
10.    Other Applications

Countries – Market of 25 Countries Covered:

1.    North America

1.1    United States
1.2    Canada

2.    Europe

2.1    France
2.2    Germany
2.3    Italy
2.4    Spain
2.5    United Kingdom
2.6    Belgium
2.7    Netherlands
2.8    Turkey

3.    Asia Pacific

3.1    China
3.2    Japan
3.3    India
3.4    South Korea
3.5    Thailand
3.6    Malaysia
3.7    Indonesia
3.8    Australia
3.9    New Zealand

4.    Latin America

4.1    Brazil
4.2    Mexico
4.3    Argentina

5.    Middle East & Africa

5.1    Saudi Arabia
5.2    UAE
5.3    South Africa

All companies have been covered from 3 viewpoints:

•    Overview
•    Recent Development
•    Revenue

Company Analysis:

1.    Pfizer, Inc.
2.    Novartis International AG
3.    Sanofi
4.    Boehringer Ingelheim
5.    Bristol-Myers Squibb
6.    Teva Pharmaceutical Industries Ltd.
7.    ELI Lilly and Company
8.    GlaxoSmithKline0
9.    Merck & Co., Inc.
10.    Abbvie Inc.

Report Details: